Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumabMult. Scler. 2022 Jul 20;[EPub Ahead of Print], M Johnsson, HH Farman, K Blennow, H Zetterberg, C Malmeström, M Axelsson, J Lycke
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.